Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-005760-99 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To study the effect of midodrine against the symptoms of orthostatic hypotension
The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 9 overnight stays.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Midodrine HCl | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Midodrine HCl | Drug | dose at subject's current dose level |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent of Subjects Who Failed to Maintain a Response | Failure to maintain a response was defined as any randomized subject that met both criterion 1 and criterion 2 below on Day 16: 1. The Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score increased by >=4 points compared to baseline. OHSA Item 1 is a dizziness scale that is scored on a range from 0 (no dizziness) to 10 (severe dizziness). A lower score indicates less severe symptoms. 2. There was an increase in the number of syncopal/near syncopal events or severity of events within 15 minutes of standing compared to those observed at baseline. Syncope was defined as a loss of consciousness, and near syncope was defined as a feeling (e.g., dizziness, lightheadedness, feeling faint, feeling as though one would black out) that, without intervention, would lead to a loss of consciousness. | 30 minutes post-dose on Day 16 |
Not provided
Not provided
Inclusion Criteria:
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| California Clinical Trials Medical Group | Glendale | California | 91206 | United States | ||
| Pharmaseek-Burbank |
Subjects received the dose and frequency of Midodrine HCl that they had been receiving during their non-study treatment prior to enrolling in this study.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Midodrine HCl - (Open-label) | On the morning of Day -1, subjects took their usual morning dose of midodrine HCl, using their own midodrine HCl supplies at approximately the same time before rising that they would normally take their morning dose. On the morning of Day 1, subjects had their usual morning dose of midodrine HCl withheld. On Day 2, all eligible subjects continued on their midodrine HCl dose regimen over at least 14 days, using study-supplied investigational product. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Part A (Open-label) |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | single dose of matching placebo |
|
| North Hollywood |
| California |
| 91606 |
| United States |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida | 33486 | United States |
| Advance Research Institute Inc | New Port Richey | Florida | 34653 | United States |
| DMI Reasearch Inc | Pinellas Park | Florida | 33782 | United States |
| Parkinson's Disease Treatment Center of Southwest Florida | Port Charlotte | Florida | 33980 | United States |
| Chicago Medical VA | North Chicago | Illinois | 60064 | United States |
| Analab Clinical Research Inc | Lenexa | Kansas | 66219 | United States |
| PAREXEL International - Baltimore EPCU Harbor Hospital | Baltimore | Maryland | 21225 | United States |
| Frontage Clinical Services | Hackensack | New Jersey | 07601 | United States |
| Buffalo Clinical Research Center (BCRC) | Buffalo | New York | 14202 | United States |
| Columbia University | New York | New York | 10032 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| Kidney and Hypertension Center | Roseburg | Oregon | 97471 | United States |
| New Orleans Center for Clinical Research - Knoxville | Knoxville | Tennessee | 37920 | United States |
| UT South West Medical Center | Dallas | Texas | 75390 | United States |
| The Heartbeat Clinic, PA | McKinney | Texas | 75069 | United States |
| Aspen Clinical Research | Orem | Utah | 84058 | United States |
| Fakultnà nemocnice Hradec Králové | Hradec | Králové | 500 05 | Czechia |
| Fakultnà nemocnice Ostrava | Ostrava | Poruba | 708 52 | Czechia |
| Fakultnà nemocnice v Motole | Prague | 150 06 | Czechia |
| EMC Silesia Sp. z o.o.; NZOZ Szpital Geriatryczny im. Jana Pawła II w Katowicach | Katowice | 40-353 | Poland |
| Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, + satelite site:NZOZ Szpital Avimed Sp. z o.o. | Katowice | 40-588 | Poland |
| Centrum Medyczne HCP, Lecznictwo Stacjonarne, Oddział Udarowy | Poznan | 61-485 | Poland |
| MTZ Clinical Research Sp. z o.o. | Warsaw | 02-106 | Poland |
| Wojskowy Instytut Medyczny, Klinika Neurologiczna | Warsaw | 04-141 | Poland |
| Neurologická klinika SZU a UNB, Univerzitná nemocnica Bratislava | Bratislava | 826 06 | Slovakia |
| Neurologická klinika UN Martin, Univerzitná nemocnica Martin | Martin | 036 59 | Slovakia |
| Neurologická klinika FN Nitra, Fakultná nemocnica Nitra | Nitra | 949 01 | Slovakia |
| Neurologické oddelenie, Nemocnica s poliklinikou Spišská Nová Ves, a.s. | Spišská Nová Ves | 052 01 | Slovakia |
| Neurologické oddelenie FN Trnava, Fakultná nemocnica Trnava | Trnava | 917 75 | Slovakia |
| Neurologické oddelenie FNsP Žilina, Fakultná nemocnica s poliklinikou Žilina | Žilina | 012 07 | Slovakia |
| FG001 | Midodrine HCl - (Randomized) | On Day 16 subjects received over-encapsulated midodrine HCl tablets (equivalent to their previously prescribed dose). |
| FG002 | Placebo - (Randomized) | On Day 16 subjects received matching placebo. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Part B (Open-label) |
|
|
| Part C (Randomized) |
|
The Enrolled Population consisted of all subjects who participated in Part A baseline procedures starting at Day -1.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Enrolled Population |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent of Subjects Who Failed to Maintain a Response | Failure to maintain a response was defined as any randomized subject that met both criterion 1 and criterion 2 below on Day 16: 1. The Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score increased by >=4 points compared to baseline. OHSA Item 1 is a dizziness scale that is scored on a range from 0 (no dizziness) to 10 (severe dizziness). A lower score indicates less severe symptoms. 2. There was an increase in the number of syncopal/near syncopal events or severity of events within 15 minutes of standing compared to those observed at baseline. Syncope was defined as a loss of consciousness, and near syncope was defined as a feeling (e.g., dizziness, lightheadedness, feeling faint, feeling as though one would black out) that, without intervention, would lead to a loss of consciousness. | The Full Analysis Set was defined as all randomized subjects who received at least 1 dose of double-blind investigational product. | Posted | Number | percentage of participants | 30 minutes post-dose on Day 16 |
|
|
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Midodrine HCl - Open-label (Part A) | dose at the subjects current dose level | 0 | 98 | 5 | 98 | ||
| EG001 | Midodrine HCl - Open-label (Part B) | open-label study-supplied (Part B) dose at subjects current dose level | 0 | 71 | 2 | 71 | ||
| EG002 | Midodrine HCl - Randomized (Part C) | over-encapsulated randomized dose (Part C) at subjects current dose level | 0 | 33 | 0 | 33 | ||
| EG003 | Placebo - Randomized (Part C) | over-encapsulated randomized matching placebo | 0 | 34 | 0 | 34 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders |
|
If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Shire | +1 866 842 5335 | ClinicalTransparency@shire.com |
| ID | Term |
|---|---|
| D008879 | Midodrine |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D000588 | Amines |
Not provided
Not provided
| Poland |
|